Trial · NCT03332173
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Major Response Rate (MRR) as Assessed by the Independent Review Committee | Zanubrutinib | 69.8 | 95% Confidence Interval 53.87 to 82.82 | Percentage of participants | |
| Progression Free Survival (PFS) | Zanubrutinib | NA | 95% Confidence Interval 16.53 to NA | Months | |
| PFS: Event-free Rate | Zanubrutinib | 6 months | 89.8 | 95% Confidence Interval 75.1 to 96.1 | Percentage of participants |
| PFS: Event-free Rate | Zanubrutinib | 9 months | 87.0 | 95% Confidence Interval 71.5 to 94.4 | Percentage of participants |
| PFS: Event-free Rate | Zanubrutinib | 12 months | 77.8 | 95% Confidence Interval 60.2 to 88.3 | Percentage of participants |
| Overall Response Rate (ORR) | Zanubrutinib | 79.1 | 95% Confidence Interval 63.96 to 89.96 | Percentage of participants | |
| Duration of Major Response (DOMR) | Zanubrutinib | NA | 95% Confidence Interval 13.77 to NA | Months | |
| DOMR: Event-free Rate | Zanubrutinib | 6 months | 96.2 | 95% Confidence Interval 75.7 to 99.4 | Percentage of participants |
| DOMR: Event-free Rate | Zanubrutinib | 9 months | 87.0 | 95% Confidence Interval 64.7 to 95.6 | Percentage of participants |
| DOMR: Event-free Rate | Zanubrutinib | 12 months | 87.0 | 95% Confidence Interval 64.7 to 95.6 | Percentage of participants |
| Number of Participants With Resolution of Treatment-precipitating Symptoms | Zanubrutinib | 35 | Participants | ||
| Number of Participants With an Anti-lymphoma Effect | Zanubrutinib | 34 | Participants | ||
| Number of Participants With Adverse Events | Zanubrutinib | At least one TEAE | 44 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | Grade 3 or higher TEAEs | 34 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | Serious TEAEs | 25 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | Treatment-related TEAEs | 41 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | TEAEs of special interest | 43 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | TEAEs leading to study drug discontinuation | 5 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | TEAEs leading to treatment interruption | 17 | Participants | |
| Number of Participants With Adverse Events | Zanubrutinib | TEAEs leading to dose reduction | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03332173/results